Merck’s Winrevair: A Catalyst for Stock Growth Amid Promising Clinical Developments
In a report released on January 30, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...
Billboard14d
Bubbling Under Hot 100
bubbling under hot 100 the week’s most popular current songs across all genres below no. 100, ranked by streaming activity data by online music sources tracked by luminate, radio airplay ...
Business Insider24d
Merck & Company: Strategic Shifts and Upcoming Catalysts Amidst Keytruda Challenges
Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target to $119.00. Discover outperforming stocks and invest ...
BioSpace24d
JPM25 Day Two: Roche, Amgen, Merck, Lilly and Biogen
JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in the coming year. After an explosive opening marked by a suite of ...
FiercePharma24d
JPM25: BMS, Pfizer and Merck CEOs address key patent cliffs and plans to replace sales
In separate presentations, the CEOs of Bristol Myers Squibb, Pfizer and Merck laid out their plans to overcome high-profile losses of exclusivity (LOEs) slated to dent sales through the end of the ...
Bloomberg L.P.25d
Merck Sees 2025 Launch for Simpler Version of Cancer Drug Keytruda
Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year, accelerating the company’s efforts to protect its top ...
BioPharma Dive25d
JPM25: Amgen’s defense, Merck’s patent ‘hill’ and Viking’s long-term planning
Executives at Amgen made the case for MariTide’s differentiation, while Merck’s CEO contended that Keytruda’s coming loss of exclusivity can be managed. SAN FRANCISCO — For any hopes the dealmaking ...